Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
unknown
📅 Published: 2025-07-14 13:17
📰 Source: Yahoo
📝 Words: 18
📝 Article Content
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
📄 Summary
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-07-14 15:41:39
Updated At:
2025-07-14 15:41:39
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A